Botensilimab
As of the edition of 20 October 2026, Botensilimab is an antibody: in active development; acts on CTLA4.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2028
- Kind
- Antibody
- Registered trials
- 37, 3 stopped early
- Disease areas
- Cancer; Digestive system; Hormones; Pregnancy and women's health; Urinary and reproductive; Lungs and airways
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CTLA4 | Cytotoxic T-lymphocyte protein 4 | P16410 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 0 | 0 | 0 |
| Phase 1 | 7 | 2 | 4 | 1 |
| Phase 2 | 26 | 1 | 23 | 1 |
| Phase 3 | 3 | 0 | 2 | 1 |
| All trials | 37 |